UnknownNot Applicable

AKI Biomarkers in Coronavirus(COVID)-19

United Kingdom30 participantsStarted 2020-08-20

Plain-language summary

This research aims to investigate the role of daily measurement of urinary cell cycle arrest markers and other serum and urinary biomarkers to predict the development of acute kidney injury in critically ill patients with COVID-19 and acute respiratory disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Moderate or severe respiratory disease as defined by Berlin criteria
✓. COVID-19 positive
✓. Age ≥ 18 years

Exclusion criteria

✕. pre-existing AKI
✕. severe chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) \<20ml/min
✕. end-stage renal failure on regular dialysis
✕. kidney transplant within the last 12 months
✕. pregnancy
✕. breastfeeding

What they're measuring

Any stage of acute kidney injury

Timeframe: 7 days

Trial details

NCT IDNCT04408248

SponsorGuy's and St Thomas' NHS Foundation Trust

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-31

Contact for this trial

Marlies Ostermann, MD, PhD

0044 207 188 3038 Marlies.Ostermann@gstt.nhs.uk

View on ClinicalTrials.gov More COVID trials